Case Report
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 6, 2019; 7(19): 3104-3110
Published online Oct 6, 2019. doi: 10.12998/wjcc.v7.i19.3104
Type I neurofibromatosis with spindle cell sarcoma: A case report
Yu Zhang, Jiao-Jiao Chao, Xiu-Feng Liu, Shu-Kui Qin
Yu Zhang, Jiao-Jiao Chao, BaYi Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210000, Jiangsu Province, China.
Xiu-Feng Liu, Shu-Kui Qin, Department of Oncology, BaYi Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing 210000, Jiangsu Province, China.
Author contributions: Zhang Y and Chao JJ collected the data; Zhang Y, Chao JJ, and Liu XF wrote the paper; Qin SK proofread the paper.
Informed consent statement: Informed written consent was obtained from the patient.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Shu-Kui Qing, MD, Chief Doctor, Professor, Medical Oncology Department, PLA Cancer Center, Nanjing Bayi Hospital, Department of Oncology, the 81 Hospital of the Chinese People’s Liberation Army, No. 34 Yanggongjing Street, Nanjing 210002, Jiangsu Province, China. qinsk@csco.org.cn
Telephone: +86-25-84453932 Fax: +86-25-84453906
Received: June 11, 2019
Peer-review started: June 19, 2019
First decision: August 1, 2019
Revised: September 8, 2019
Accepted: September 11, 2019
Article in press: September 11, 2019
Published online: October 6, 2019
Core Tip

Core tip: Neurofibromatosis type I with malignant tumor is very rare. Because of its rarity in clinical practice, there are many uncertainties in the selection of treatment regimens. Therefore, it is necessary to study the effective and reasonable standard treatment regimens. We present a case of neurofibromatosis type I with soft tissue sarcoma. Since there is limited evidence of targeted therapy for this disease, the selection of treatment strategies should be based on rich clinical experience and research.